
|Articles|December 5, 2012
NDA accepted for kidney cancer agent
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves tebipenem pivoxil for complicated urinary tract infections
2
Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC
3
Jenny Guo, MD, discusses outcomes with hemi-HoLEP after pelvic radiation
4
Daniel Eun, MD, on telesurgery, AI, and the future of reconstructive urology
5











